desonide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
steroids for topical use, acetal derivatives 3135 638-94-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • desonide
  • budesonide acetonide
  • prednacinolone
A nonfluorinated corticosteroid anti-inflammatory agent used topically for DERMATOSES.
  • Molecular weight: 416.51
  • Formula: C24H32O6
  • CLOGP: 2.37
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 93.06
  • ALOGS: -3.85
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.029 Moderate 0.73
caco2-efflux Caco-2 efflux ratio (BA/AB) 3.963 Moderate 0.73
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 43.652 10^-6 cm/s Moderate 0.73
dh-clint Dog hepatocyte intrinsic clearance 8.974 uL/min/10^6 cells Moderate 0.73
dppb Dog plasma protein binding (% unbound) 28.620 % Moderate 0.73
fcs-ppb Fetal calf serum protein binding (% unbound) 37.980 % Moderate 0.73
herg hERG pIC50 4.305 pIC50 Moderate 0.73
hh-clint Human hepatocyte intrinsic clearance 6.982 uL/min/10^6 cells Moderate 0.73
hlm-clint Human liver microsomal intrinsic clearance 36.224 uL/min/mg protein Moderate 0.73
hppb Human plasma protein binding (% unbound) 23.070 % Moderate 0.73
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK 18
kinase-selectivity-class GRK2,MAP2K6 2
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 3.707 Moderate 0.73
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 9.247 Moderate 0.73
mh-clint Mouse hepatocyte intrinsic clearance 28.054 Moderate 0.73
mppb Mouse plasma protein binding (% unbound) 25.830 Moderate 0.73
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 17.378 Moderate 0.73
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.67
pppb Pig plasma protein binding (% unbound) 35.620 % Moderate 0.73
rat-kpuu-brain Rat brain Kpuu 0.029 % Moderate 0.73
rh-clint Rat hepatocyte intrinsic clearance 39.084 uL/min/10^6 cells Moderate 0.73
rh-fuinc Rat hepatocyte fraction unbound in incubation 76.480 % Moderate 0.73
rppb Rat plasma protein binding (% unbound) 18.290 % Moderate 0.73
solubility-dd Solubility at pH 7.4 in DMSO 662.217 uM Moderate 0.73

Approvals:

DateAgencyCompanyOrphan
Jan. 4, 1972 FDA PERRIGO NEW YORK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 1445.90 23.17 399 9240 37571 90581237
Chronic sinusitis 507.24 23.17 160 9479 23642 90595166
Paraesthesia oral 412.57 23.17 147 9492 31512 90587296
Vaginal flatulence 403.14 23.17 116 9523 12522 90606286
Female genital tract fistula 388.41 23.17 122 9517 17746 90601062
Radiculopathy 384.20 23.17 122 9517 18383 90600425
Proctitis 381.55 23.17 116 9523 15143 90603665
Vaginal discharge 357.80 23.17 117 9522 19347 90599461
Procedural pain 342.53 23.17 130 9509 33230 90585578
Drug ineffective 337.59 23.17 555 9084 1383743 89235065
Oral candidiasis 289.32 23.17 117 9522 35338 90583470
Dermatitis atopic 272.02 23.17 100 9539 23372 90595436
Haematochezia 242.73 23.17 128 9511 70785 90548023
Frequent bowel movements 242.12 23.17 119 9520 56816 90561992
Colitis ulcerative 241.59 23.17 121 9518 60145 90558663
Rectal haemorrhage 232.33 23.17 131 9508 82613 90536195
Therapeutic product effect incomplete 231.94 23.17 180 9459 193716 90425092
Colitis 224.59 23.17 121 9518 69821 90548987
Erythema 213.60 23.17 184 9455 229062 90389746
Dyspepsia 145.00 23.17 139 9500 198021 90420787
Weight decreased 117.00 23.17 171 9468 379739 90239069
Constipation 97.74 23.17 134 9505 280261 90338547
Dry skin 90.61 23.17 75 9564 87998 90530810
Psoriasis 84.83 23.17 91 9548 147663 90471145
Abdominal pain 75.76 23.17 144 9495 395577 90223231
Eczema 73.90 23.17 54 9585 52816 90565992
Anaemia 70.76 23.17 131 9508 352671 90266137
Skin exfoliation 70.18 23.17 58 9581 67855 90550953
Malaise 62.51 23.17 169 9470 585817 90032991
Infusion related reaction 60.10 23.17 135 9504 416645 90202163
Pyrexia 55.56 23.17 175 9464 660310 89958498
Anhidrosis 51.96 23.17 10 9629 182 90618626
Nausea 50.53 23.17 242 9397 1110074 89508734
Pain 40.17 23.17 210 9429 996131 89622677
Pruritus 38.77 23.17 136 9503 541389 90077419
Cutaneous T-cell lymphoma 34.90 23.17 11 9628 1609 90617199
Joint swelling 32.40 23.17 7 9632 503293 90115515
Headache 32.10 23.17 178 9461 862568 89756240
Off label use 31.30 23.17 212 9427 1102040 89516768
Skin plaque 31.23 23.17 17 9622 9958 90608850
Skin fissures 30.76 23.17 22 9617 20787 90598021
Skin burning sensation 29.60 23.17 21 9618 19590 90599218
Systemic lupus erythematosus 27.90 23.17 3 9636 361893 90256915
Iridoschisis 26.58 23.17 4 9635 14 90618794
Sleep disorder due to a general medical condition 26.41 23.17 28 9611 44710 90574098
Hepatic enzyme increased 25.39 23.17 4 9635 360732 90258076
Synovitis 24.75 23.17 3 9636 329749 90289059
Glossodynia 23.97 23.17 3 9636 321776 90297032
Contraindicated product administered 23.81 23.17 3 9636 320136 90298672
Papule 23.30 23.17 13 9626 7989 90610819

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis atopic 168.36 22.10 55 3286 12349 42605645
Psoriasis 115.27 22.10 62 3279 48542 42569452
Skin exfoliation 76.68 22.10 45 3296 41508 42576486
Dry skin 70.40 22.10 45 3296 48293 42569701
Pruritus 58.82 22.10 73 3268 188698 42429296
Drug ineffective 38.50 22.10 122 3219 630075 41987919
Rash 36.41 22.10 72 3269 276882 42341112
Eczema 35.91 22.10 26 3315 34060 42583934
Sleep disorder due to a general medical condition 35.07 22.10 20 3321 17433 42600561
Anhidrosis 34.97 22.10 7 3334 216 42617778
Madarosis 29.26 22.10 7 3334 499 42617495
Product dose omission issue 29.06 22.10 47 3294 154318 42463676
Ocular hyperaemia 28.64 22.10 17 3324 15946 42602048
Skin burning sensation 27.88 22.10 13 3328 7474 42610520
Melanocytic naevus 27.78 22.10 10 3331 2982 42615012
Eye pruritus 25.43 22.10 14 3327 11398 42606596
Hepatic lesion 23.83 22.10 10 3331 4484 42613510
Conjunctivitis 23.79 22.10 14 3327 12925 42605069
Erythema 23.05 22.10 35 3306 108758 42509236
Cerebral artery thrombosis 22.99 22.10 7 3334 1242 42616752

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 529.19 21.09 158 10477 21501 110557163
Chronic sinusitis 506.32 21.09 158 10477 24926 110553738
Vaginal flatulence 414.60 21.09 115 10520 12029 110566635
Paraesthesia oral 414.26 21.09 146 10489 33525 110545139
Female genital tract fistula 405.55 21.09 121 10514 16398 110562266
Radiculopathy 382.58 21.09 120 10515 19216 110559448
Proctitis 376.87 21.09 115 10520 16812 110561852
Vaginal discharge 374.70 21.09 116 10519 17792 110560872
Procedural pain 343.45 21.09 129 10506 35436 110543228
Dermatitis atopic 303.60 21.09 108 10527 25433 110553231
Oral candidiasis 277.62 21.09 118 10517 44642 110534022
Frequent bowel movements 227.92 21.09 119 10516 71271 110507393
Colitis ulcerative 227.32 21.09 122 10513 77241 110501423
Rectal haemorrhage 209.46 21.09 135 10500 119698 110458966
Therapeutic product effect incomplete 205.99 21.09 171 10464 223634 110355030
Erythema 204.83 21.09 191 10444 291256 110287408
Haematochezia 201.54 21.09 130 10505 115394 110463270
Colitis 198.11 21.09 123 10512 102200 110476464
Dyspepsia 157.34 21.09 137 10498 190828 110387836
Weight decreased 118.17 21.09 182 10453 467875 110110789
Dry skin 117.46 21.09 91 10544 107562 110471102
Psoriasis 110.34 21.09 98 10537 139895 110438769
Skin exfoliation 88.91 21.09 71 10564 87580 110491084
Anhidrosis 86.18 21.09 17 10618 393 110578271
Constipation 83.06 21.09 134 10501 357652 110221012
Eczema 80.76 21.09 62 10573 72231 110506433
Abdominal pain 78.17 21.09 160 10475 512829 110065835
Infusion related reaction 76.81 21.09 134 10501 381028 110197636
Pain 64.82 21.09 220 10415 954735 109623929
Malaise 64.57 21.09 175 10460 671644 109907020
Pyrexia 62.76 21.09 209 10426 898056 109680608
Drug ineffective 59.32 21.09 295 10340 1520245 109058419
Pruritus 56.34 21.09 152 10483 581408 109997256
Madarosis 50.20 21.09 17 10618 3446 110575218
Headache 48.54 21.09 190 10445 882187 109696477
Anaemia 44.20 21.09 134 10501 546952 110031712
Sleep disorder due to a general medical condition 44.05 21.09 38 10597 52074 110526590
Nausea 42.66 21.09 232 10403 1235458 109343206
Skin burning sensation 41.56 21.09 26 10609 21799 110556865
Cutaneous T-cell lymphoma 35.27 21.09 13 10622 3371 110575293
Incorrect dose administered 34.38 21.09 46 10589 103595 110475069
Pain of skin 33.53 21.09 22 10613 20007 110558657
Eye pruritus 32.04 21.09 26 10609 32749 110545915
Eye irritation 31.57 21.09 26 10609 33426 110545238
Off label use 30.59 21.09 247 10388 1499938 109078726
Skin fissures 29.56 21.09 22 10613 24436 110554228
Rash 29.48 21.09 156 10479 820808 109757856
Dry eye 28.77 21.09 31 10604 55762 110522902
Iridoschisis 26.98 21.09 4 10631 14 110578650
Eyelid irritation 26.50 21.09 8 10627 1123 110577541
Product dose omission issue 26.10 21.09 79 10556 321703 110256961
Ocular hyperaemia 26.04 21.09 25 10610 39261 110539403
Injection site pain 25.24 21.09 54 10581 177868 110400796
Therapeutic product effect delayed 25.08 21.09 11 10624 4468 110574196
Drug interaction 24.09 21.09 9 10626 500174 110078490
Acute kidney injury 23.76 21.09 16 10619 635414 109943250
Eye swelling 21.85 21.09 21 10614 33027 110545637
Conjunctivitis 21.45 21.09 21 10614 33771 110544893
Joint swelling 21.27 21.09 8 10627 442837 110135827

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D07AB08 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, PLAIN
Corticosteroids, moderately potent (group II)
ATC D07BB02 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS
Corticosteroids, moderately potent, combinations with antiseptics
ATC S01BA11 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFLAMMATORY AGENTS
Corticosteroids, plain
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
MeSH PA D000893 Anti-Inflammatory Agents
CHEBI has role CHEBI:35472 anti-inflammatory drug

Related Drugs by ATC class:

D07AB Corticosteroids, moderately potent (group II) 12 drugs
alclometasone dipropionateclobetasone butyrateclocortolone pivalatedexamethasoneflumetasonefluocortin butylfluorometholonefluperolonefluprednidenehydrocortisone butyratehydrocortisone probutatetriamcinolone
D07BB Corticosteroids, moderately potent, combinations with antiseptics 3 drugs
flumetasonehydrocortisone butyratetriamcinolone
S01BA Corticosteroids, plain 15 drugs
alclometasone dipropionatebetamethasoneclobetasol propionateclobetasone butyratedexamethasonedifluprednatefluocinolone acetonidefluorometholoneformocortalhydrocortisoneloteprednol etabonatemedrysone show all 15 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Otitis externa indication 3135009
Atopic dermatitis indication 24079001 DOID:3310
Crohn's disease indication 34000006
Contact dermatitis indication 40275004 DOID:2773
Seborrheic dermatitis indication 50563003 DOID:8741
Lichen simplex chronicus indication 53891004
Allergic rhinitis indication 61582004
Granuloma annulare indication 65508009 DOID:3777
Pruritus ani indication 90446007
Asthma indication 195967001 DOID:2841
Discoid lupus erythematosus indication 200938002
Plaque psoriasis indication 200965009
Scalp psoriasis indication 238608008
Pruritus of genital organs indication 267802000
Eruption of skin indication 271807003 DOID:0050486
Primary cutaneous T-cell lymphoma indication 400122007
Asthma management indication 406162001
Crohn's disease in remission indication 426549001
Allergic Rhinitis Prevention indication
Chronic Non-Allergic Rhinitis indication
Severe chronic obstructive pulmonary disease off-label use 313299006
Otitis Externa Eczema off-label use
Otitis Externa Seborrhea off-label use
Infection by Strongyloides contraindication 1214006 DOID:10955
Mycosis contraindication 3218000 DOID:1564
Ocular hypertension contraindication 4210003 DOID:9282
Gastritis contraindication 4556007 DOID:4029
Inactive tuberculosis contraindication 11999007
Epistaxis contraindication 12441001
Peptic ulcer contraindication 13200003 DOID:750
Hypercholesterolemia contraindication 13644009
Measles contraindication 14189004 DOID:8622
Disease caused by parasite contraindication 17322007
Cirrhosis of liver contraindication 19943007 DOID:5082
Arginase deficiency contraindication 23501004 DOID:9278
Glaucoma contraindication 23986001 DOID:1686
Acute tuberculosis contraindication 25629007
Viral disease contraindication 34014006 DOID:934
Immunosuppression contraindication 38013005
Hypertensive disorder contraindication 38341003 DOID:10763
Infectious disease contraindication 40733004
Hypothyroidism contraindication 40930008 DOID:1459
Hypokalemia contraindication 43339004
Hypercortisolism contraindication 47270006
Chronic heart failure contraindication 48447003
Cerebral malaria contraindication 53622003 DOID:14069
Tuberculosis contraindication 56717001
Perforation of tympanic membrane contraindication 60442001
Congenital hyperammonemia, type I contraindication 62522004
Osteoporosis contraindication 64859006 DOID:11476
Psychotic disorder contraindication 69322001
Diabetes mellitus contraindication 73211009 DOID:9351
Hypopituitarism contraindication 74728003 DOID:9406
Perforation of nasal septum contraindication 80142000
Hyperglycemia contraindication 80394007 DOID:4195
Ornithine Carbamyltransferase Deficiency contraindication 80908008 DOID:9271
Open-angle glaucoma contraindication 84494001 DOID:1067
Bacterial infectious disease contraindication 87628006
Muscle atrophy contraindication 88092000 DOID:767
Herpes simplex contraindication 88594005 DOID:8566
Operation on nose contraindication 88733004
Bilateral cataracts contraindication 95722004
Seizure disorder contraindication 128613002
Disorder of muscle contraindication 129565002 DOID:423
Pulmonary tuberculosis contraindication 154283005 DOID:2957
Ophthalmic herpes simplex contraindication 186542001
Anastomosis of intestine contraindication 235407009
Disease of liver contraindication 235856003 DOID:409
Telangiectasia disorder contraindication 247479008
Edema contraindication 267038008
Pathological fracture contraindication 268029009
Diverticulitis of gastrointestinal tract contraindication 271366000
Cerebral trauma contraindication 275382005
Varicella-zoster virus infection contraindication 309465005
Osteopenia contraindication 312894000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Avascular necrosis of bone contraindication 397758007 DOID:10159
Citrullinemia contraindication 398680004 DOID:9273
Atrophoderma contraindication 399979006
Peripheral vascular disease contraindication 400047006
Traumatic rupture of tendon contraindication 415749005
Exposure to varicella contraindication 444453009
Nasal Candidiasis contraindication
Untreated Fungal Infection contraindication
Uncontrolled Bacterial Infections contraindication
Nasal Septal Ulcers contraindication
Nasal Trauma contraindication
Arginosuccinate Lyase Deficiency contraindication
Oropharyngeal Candidiasis contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.78 acidic
pKa2 12.78 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.05% VERDESO GENUS N021978 Sept. 19, 2006 DISCN AEROSOL, FOAM TOPICAL 8460641 Aug. 13, 2027 TREATMENT OF ATOPIC DERMATITIS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST CHEMBL CHEMBL

External reference:

IDSource
4018267 VUID
N0000146597 NUI
D03696 KEGG_DRUG
4018267 VANDF
C0011705 UMLSCUI
CHEBI:204734 CHEBI
CHEMBL1201109 ChEMBL_ID
D003898 MESH_DESCRIPTOR_UI
DB01260 DRUGBANK_ID
5311066 PUBCHEM_CID
7066 IUPHAR_LIGAND_ID
2889 INN_ID
J280872D1O UNII
3254 RXNORM
1093 MMSL
4550 MMSL
002199 NDDF
412363005 SNOMEDCT_US
52215008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 0115-1517 LOTION 0.50 mg TOPICAL ANDA 17 sections
LoKara HUMAN PRESCRIPTION DRUG LABEL 1 0462-0392 LOTION 0.50 mg TOPICAL ANDA 18 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 0472-0803 LOTION 0.50 mg TOPICAL ANDA 19 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 0472-0804 CREAM 0.50 mg TOPICAL NDA authorized generic 19 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 0713-0661 CREAM 0.50 mg TOPICAL ANDA 18 sections
DESONATE HUMAN PRESCRIPTION DRUG LABEL 1 10922-828 GEL 0.50 mg TOPICAL NDA 24 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 16714-729 CREAM 0.50 mg TOPICAL ANDA 21 sections
DESONIDE HUMAN PRESCRIPTION DRUG LABEL 1 21695-944 CREAM 0.50 mg TOPICAL ANDA 21 sections
Desonide Ointment, 0.05% HUMAN PRESCRIPTION DRUG LABEL 1 21922-004 OINTMENT 0.50 mg TOPICAL ANDA 18 sections
DESONIDE HUMAN PRESCRIPTION DRUG LABEL 1 24470-920 GEL 0.50 mg TOPICAL ANDA 20 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 42254-142 CREAM 0.50 mg TOPICAL NDA 20 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 45802-423 OINTMENT 0.50 mg TOPICAL NDA 20 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 46708-485 OINTMENT 0.50 mg TOPICAL ANDA 12 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 46708-550 LOTION 0.50 mg TOPICAL ANDA 10 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 46708-632 CREAM 0.50 mg TOPICAL ANDA 11 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 50436-3300 CREAM 0.50 mg TOPICAL ANDA 18 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 51672-1280 CREAM 0.50 mg TOPICAL ANDA 21 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 51672-1281 OINTMENT 0.50 mg TOPICAL ANDA 21 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 51672-4079 LOTION 0.50 mg TOPICAL ANDA 21 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 52565-038 OINTMENT 0.50 mg TOPICAL ANDA 20 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 54868-3284 CREAM 0.50 mg TOPICAL NDA 20 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 54868-4453 OINTMENT 0.50 mg TOPICAL NDA 20 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 54868-5050 LOTION 0.50 mg TOPICAL ANDA 19 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 62332-485 OINTMENT 0.50 mg TOPICAL ANDA 12 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 62332-550 LOTION 0.50 mg TOPICAL ANDA 10 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 62332-632 CREAM 0.50 mg TOPICAL ANDA 11 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 63187-747 CREAM 0.50 mg TOPICAL NDA authorized generic 19 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 63629-2506 CREAM 0.50 mg TOPICAL ANDA 17 sections
Desonide HUMAN PRESCRIPTION DRUG LABEL 1 63629-2507 CREAM 0.50 mg TOPICAL ANDA 17 sections
Desonide Ointment, 0.05% HUMAN PRESCRIPTION DRUG LABEL 1 63629-8481 OINTMENT 0.50 mg TOPICAL ANDA 18 sections